Wockhardt Puts Up Superbug Fight With Punchy Broad Spectrum Antibiotic
Executive Summary
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
You may also be interested in...
Cipla-SIGA Antibacterial Alliance To Tackle Resistance, Biothreats
Cipla, which has long-standing experience in antibiotic development in India, strikes alliance with US firm SIGA Technologies. The partners are targeting novel antibacterials, especially against biothreats, and expect to cater to US agency BARDA, among others.
One More On QIDP List – Does It Help Wockhardt?
Wockhardt has received QIDP designation in the US for its once-daily zidebactam-based combination antibiotic WCK 6777, taking to six its portfolio products with the status. But unless the FDA gives a clean sheet to the company’s major manufacturing units, this won't help US revenues
Wockhardt Will Raise Funds With Restructuring
India’s Wockhardt has announced its first profit in three years and says a restructuring plan will be carried out soon.